HEALTHSTORY 660· JUNE 21, 2026

GLP-1 Weight Loss Drug Race Heats Up as Pfizer and Amgen Challenge Novo Nordisk and Eli Lilly

The scramble to compete in the GLP-1 weight loss drug market is intensifying. Pharmaceutical companies Pfizer and Amgen are developing products to take on Novo Nordisk's Wegovy and Eli Lilly's Zepbound

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 659Fentanyl-Linked Chinese Network Ran Fake 'Zksync.jp' Token Scam, Nikkei Reports, With Losses Topping $1 Million NEXT STORY 661 →Pomerantz Files Class Action Against ServBanc Holdco, IF Bancorp Board Over IROQ Stock

Keep reading

More from the desk.

26HEALTH

Seven months after launch, Aurora Therapeutics scraps its lead gene-editing program and cuts staff

Personalized CRISPR therapies, gene-editing treatments built around one patient's specific mutation rather than a disease shared by millions, just lost one of their early backers. Aurora Therapeutics has scrapped its lead program and laid…

health2 MIN

41HEALTH

California Supreme Court rules Gilead Sciences has no legal duty to fast-track a safer HIV drug

Pharmaceutical companies do not owe patients a legal duty to speed up development of a safer drug simply because a less safe version is already on the market. That concept, called a "duty to innovate," was at the center of a case brought…

health2 MIN

52HEALTH

Trump administration shifts 340B drug program from upfront discounts to rebates, drawing hospital backlash

A federal law requires pharmaceutical manufacturers to sell discounted medicines to specific hospitals and clinics. That discount mechanism, the foundation of the 340B Drug Pricing Program, is now being reshaped. The Trump administration…

health2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk